Buprenorphine HIV Care Integration Project
HIV Infection, Opioid-Related Disorders
About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV Infection, Opioid dependence, DSM-IV criteria for opioid dependence
Eligibility Criteria
Inclusion Criteria: HIV infection Receiving or seeking outpatient HIV care Seeking outpatient treatment for opioid dependence and be willing to take buprenorphine Meets DSM-IV criteria for opioid dependence, and be willing to stop illicit opioid use and be experiencing early symptoms of opioid withdrawal at the time that buprenorphine is given Men and women age ≥ 18 years Women of reproductive potential must have a negative serum or urine pregnancy test result available within 7 days prior to initiating buprenorphine Within 30 days: (SGOT), ALT (SGPT), and alkaline phosphatase <=5 X ULN, Total bilirubin <= 2.5 x ULN Exclusion Criteria: Serious medical problem Acute and/or severe psychiatric conditions High dose methadone (>30 mg/day) Documented co-dependence on alcohol and/or benzodiazepines, barbiturates Chronic pain management requiring opioids Pregnancy or breast-feeding Imprisonment or involuntary incarceration in a medical facility for psychiatric or physical
Sites / Locations
- University of Miami AIDS Clinical Reserach Unit
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2
enhanced behavioral motivation counseling